Elevated Neopterin Levels in Guillain-Barre Syndrome: Further Evidence of Immune Activation

Shalini Bansil, Stuart D. Cook, Christine Rohowsky Kochan, Francis A. Mithen, Bhim S. Singhal

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Neopterin is a by-product of guanosine triphosphate metabolism and is produced by macrophages in response to lymphocytic activation. We have studied serum neopterin levels in patients with Guillain-Barré syndrome to obtain further evidence of immune activation in this disease. Serum neopterin levels were significantly elevated in patients with Guillain-Barré syndrome compared with patients with other peripheral neuropathies and multiple sclerosis and with healthy control subjects. Serial analysis demonstrated that as neopterin levels fell, the clinical status of the patients with Guillain-Barré syndrome improved and soluble interleukin 2 receptor levels dropped. Thus, lymphocytic and macrophage activation may play a role in the pathogenesis of Guillain-Barré syndrome.

Original languageEnglish (US)
Pages (from-to)1277-1280
Number of pages4
JournalArchives of Neurology
Volume49
Issue number12
DOIs
StatePublished - Dec 1992

All Science Journal Classification (ASJC) codes

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Elevated Neopterin Levels in Guillain-Barre Syndrome: Further Evidence of Immune Activation'. Together they form a unique fingerprint.

Cite this